Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
University of Southern California, Los Angeles, California START Midwest, Grand Rapids, Michigan The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio The University of Texas MD Anderson Cancer Center, Houston, Texas Japan
National Cancer Center Hospital, Chuo-Ku, Tokyo National Cancer Center Hospital East, City